Atossa Q3 Revenues Fall 27 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics reported on Tuesday that revenues in its third quarter dropped 27 percent year over year.

It also said it inked a new deal with Aspire Capital for the sale of up to $25 million in common stock during the next 30 months.

For the three months ended Sept. 30, Atossa posted $76,597 in revenues, down from $105,576 a year ago. Diagnostic testing service revenues slipped to $72,187 from $104,011, while product sales increased to $4,400 from $1,565.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.